NCT05254626View on ClinicalTrials.gov

Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 23, 2024

Study Completion Date

July 23, 2024

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

Dapagliflozin 10Mg Tab

Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.

DRUG

Pioglitazone 30 mg

Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.

Trial Locations (1)

Unknown

National Hepatology and Tropical Medicine Research Institute, Cairo

All Listed Sponsors
lead

Cairo University

OTHER